By Austin Hankwitz, Rate of Return by Austin Hankwitz, 2024-06-24
Welcome to your new week.
Before we dive in — let's talk through something that I always talk about on the Rich Habits podcast. It's super simple — that's loving up on some ETFs!
Whether it's examples like VGT, SPYI, QQQI, or VOO (below) — there's a reason why it can be great to build the base of a portfolio with ETFs.
They're cheap, liquid, have mass institutional adoption, have consistently-proven upside, and some of them (like SPYI and QQQI) can provide enhanced monthly income potential.
Thanks so much to the 10s of thousands of you that listen to Rich Habits each week. Below is a link to this morning's episode — which is all about to find an extra few thousand dollars per year in your budget to begin investing. This episode is especially helpful if you're someone who's living paycheck to paycheck.
Key Earnings Announcements:
Nike and Micron lead the way.
You may also like
Fed Minutes Loom with Biotech, AI and Crypto Moves
Market Pulse: After Asia’s late rally fizzled, US futures drifted into the close, leaving traders...
Guggenheim’s $8 Target: BDTX’s Phase 2 Results Ahead!
Black Diamond Therapeutics (NASDAQ: BDTX) is a clinical-stage oncology company that has recently...
Turbocharged Market Rundown: Biotech, Crypto, M&A Alerts
Daily Financial Update Good morning—here’s your quick-hit, no-BS briefing on yesterday’s biggest...
AZN: Tagrisso Boost Could Skyrocket AstraZeneca’s Value!
Overview – Tagrisso as a Growth Engine AstraZeneca (AZN) has transformed itself into a pharma...
MemeCore Rally, Savara Lawsuit Shake Biotech Bulls
Market Pulse Overnight volatility shattered the monotony as a retail frenzy around MemeCore sent...
“ADAP Short Interest Spikes 127%—Why This Matters Now!”
Overview of Adaptimmune Therapeutics (ADAP) Adaptimmune Therapeutics (NASDAQ: ADAP) is a clinical...